About pcm
Manuscript Submission
AME Editing Service
Reprint & Permission
Advertising
Contact us
-
General editorial enquiries:
Email: pcm@amegroups.com -
Copyright related contact:
Email: permissions@amegroups.com -
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com
Original Article
Precision Cancer Medicine
2024;
6:
5
(30 September 2024)
Case Report
Precision Cancer Medicine
2024;
6:
4
(30 September 2024)
Review Article
Precision Cancer Medicine
2024;
6:
3
(30 September 2024)
Review Article
Precision Cancer Medicine
2024;
6:
2
(30 September 2024)
Review Article
Precision Cancer Medicine
2024;
6:
1
(30 September 2024)
Editorial Commentary
Precision Cancer Medicine
2023;
6:
20
(30 June 2023)
Case Report
Precision Cancer Medicine
2023;
6:
19
(30 June 2023)
Case Report
Precision Cancer Medicine
2023;
6:
18
(30 June 2023)
Case Report
Precision Cancer Medicine
2023;
6:
17
(30 June 2023)
Case Report
Precision Cancer Medicine
2023;
6:
16
(30 June 2023)
Review Article
Precision Cancer Medicine
2023;
6:
15
(30 June 2023)
Review Article
Precision Cancer Medicine
2023;
6:
14
(30 June 2023)
Review Article
Precision Cancer Medicine
2023;
6:
13
(30 June 2023)
Editorial
Precision Cancer Medicine
2023;
6:
12
(30 June 2023)
Editorial
Precision Cancer Medicine
2023;
6:
11
(30 June 2023)
Case Report
Precision Cancer Medicine
2023;
6:
10
(30 March 2023)
Case Report
Precision Cancer Medicine
2023;
6:
9
(30 March 2023)
Review Article
Precision Cancer Medicine
2023;
6:
8
(30 March 2023)
Review Article
Precision Cancer Medicine
2023;
6:
7
(30 March 2023)
Review Article
Precision Cancer Medicine
2023;
6:
6
(30 March 2023)
Review Article
Original Article
Review Article
Case Report: Precision Oncology Tumor Board
Review Article
Review Article
Review Article
Review Article: Precision Oncology Tumor Board
Review Article
Editorial
Review Article
Review Article
Review Article
Review Article
Review Article
Review Article
Case Report
Editorial Commentary
Review Article
Review Article
Review Article
Case Report: Precision Oncology Tumor Board